Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Stephen E. Fawell Clear advanced filters

  • Resistance to first line treatment is a major hurdle in cancer treatment, that can be overcome with drug combinations. Here, the authors provide a large drug combination screen across cancer cell lines to benchmark crowdsourced methods and to computationally predict drug synergies.

    • Michael P. Menden
    • Dennis Wang
    • Julio Saez-Rodriguez
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-17

  • DNA-dependent protein kinase (DNA-PK) plays a major role in the DNA damage response upon double-strand break formation. Here, the authors show that the DNA-PK inhibitor AZD7648, enhances the activity of radiotherapy, chemotherapy and the PARP inhibitor olaparib in multiple mouse tumour models.

    • Jacqueline H. L. Fok
    • Antonio Ramos-Montoya
    • Elaine B. Cadogan
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-15

  • Deregulated Wnt pathway activity has been implicated in many cancers, making this pathway an attractive target for anticancer therapies. Here, a small molecule inhibitor of the Wnt pathway is identified and its direct target and mechanism of action are characterized, providing new insights into the physiological regulation of the Wnt pathway and new possibilities for targeted Wnt pathway therapeutics.

    • Shih-Min A. Huang
    • Yuji M. Mishina
    • Feng Cong
    Research
    Nature
    Volume: 461, P: 614-620

  • High expression of Mcl-1 promotes tumorigenesis and resistance to anticancer therapies. Here they report a macrocyclic molecule with high selectivity and affinity for Mcl-1 that exhibits potent anti-tumor effects as single agent and in combination with bortezomib or venetoclax in preclinical models of multiple myeloma and acute myeloid leukemia.

    • Adriana E. Tron
    • Matthew A. Belmonte
    • Alexander W. Hird
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-14

  • Claire Patterson et al. present the design and development of AZD0466, a drug-dendrimer conjugate, and use preclinical and mathematical models to determine the optimal release rate of the drug from the dendrimer carrier for maximal therapeutic index in terms of anti-tumour efficacy and cardiovascular tolerability. This study identifies this promising dual Bcl-2/Bcl-xL inhibitor for progression to clinical development.

    • Claire M. Patterson
    • Srividya B. Balachander
    • Marianne B. Ashford
    ResearchOpen Access
    Communications Biology
    Volume: 4, P: 1-14